Trial reportHepatology (Baltimore, Md.)2017
Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.
Trial report in Hepatology (Baltimore, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- A bibliometric analysis of immunotherapy for chronic hepatitis B: trends and hotspots prediction.Frontiers in immunology · 2026Pooled it
- Therapeutic vaccination strategy targeting the PreS1 region of L-HBsAg for HBV/HDV co-infection.JHEP reports : innovation in hepatology · 2026Article
- Engineering a dual-antigen mRNA vaccine to restore immune control in chronic hepatitis B.Nature communications · 2026Article
- A Multivalent mRNA Therapeutic Vaccine Exhibits Breakthroughs in Immune Tolerance and Virological Suppression of HBV by Stably Presenting the Pre-S Antigen on the Cell Membrane.Pharmaceutics · 2025Article
- Icarisid Ⅱ modulates mitochondrial dynamics for anti-HBV activity.Frontiers in pharmacology · 2025Article
- Lipid nanoparticle-encapsulated DOCK11-siRNA efficiently reduces hepatitis B virus cccDNA level in infected mice.Molecular therapy. Methods & clinical development · 2024Article
- Mutations in the S gene of hepatitis B virus in three generations of patients with chronic hepatitis B.Virus genes · 2023Article
- Article
- Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.Gut · 2023Article
- The Multiple Facets and Disorders of B Cell Functions in Hepatitis B Virus Infection.Journal of clinical medicine · 2023Review
- Optimized Cationic Lipid-assisted Nanoparticle for Delivering CpG Oligodeoxynucleotides to Treat Hepatitis B Virus Infection.Pharmaceutical research · 2023Article
- Hepatitis B Therapeutic Vaccine: A Patent Review.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Cholesterol accumulation on dendritic cells reverses chronic hepatitis B virus infection-induced dysfunction.Cellular & molecular immunology · 2022Article
- Novel therapeutic strategies for chronic hepatitis B.Virulence · 2022Review
- CpG-C ODN M362 as an immunoadjuvant for HBV therapeutic vaccine reverses the systemic tolerance against HBV.International journal of biological sciences · 2022Article
- Efficient cellular and humoral immune response and production of virus-neutralizing antibodies by the Hepatitis B Virus S/preS1Frontiers in immunology · 2022Article
- Viral Hepatitis - The Road Traveled and the Journey Remaining.Hepatic medicine : evidence and research · 2022Review
- Treatments for HBV: A Glimpse into the Future.Viruses · 2021Review
- Identification of novel hepatitis B virus therapeutic vaccine candidates derived from polymerase protein.Aging · 2021Article
- Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections.The Journal of infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
Strong tolerance to hepatitis B virus (HBV) surface antigens limits the therapeutic effect of the conventional hepatitis B surface antigen (HBsAg) vaccination in both preclinical animal models and patients with chronic hepatitis B (CHB) infection. In contrast, we observed that clinical CHB patients presented less immune tolerance to the preS1 domain of HBV large surface antigen. To study whether targeting the weak tolerance of the preS1 region could improve therapy gain, we explored vaccination with the long peptide of preS1 domain for HBV virions clearance. Our study showed that this preS1-polypeptide rather than HBsAg vaccination induced robust immune responses in HBV carrier mice. The anti-preS1 rapidly cleared HBV virions in vivo and blocked HBV infection to hepatocytes in vitro. Intriguingly, vaccination of preS1-polypeptide even reduced the tolerized status of HBsAg, opening a therapeutic window for the host to respond to the HBsAg vaccine. A sequential administration of antigenically distinct preS1-polypeptide and HBsAg vaccines in HBV carrier mice could finally induce HBsAg/hepatitis B surface antibody serological conversion and clear chronic HBV infection in carrier mice.
conclusionThese results suggest that preS1 can function as a therapeutic vaccine for the control of CHB. (Hepatology 2017;66:1067-1082).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.